We have located links that may give you full text access.
TARGETED RNA-SEQUENCING: A ROUTINE ANCILLARY TECHNIQUE IN THE DIAGNOSIS OF BONE AND SOFT TISSUE NEOPLASMS.
Genes, Chromosomes & Cancer 2018 October 23
The past decade has witnessed remarkable progress in delineating the molecular pathogenesis of many mesenchymal neoplasms. This, in large part, is attributable to the application of next-generation sequencing. As these techniques decrease in cost, and increasingly support the use of routine clinical specimens - such as formalin-fixed paraffin-embedded tissue, and cytology samples - they are beginning to be routinely implemented in diagnostic pathology laboratories. The breath of testing possible by next-generation sequencing makes this a useful adjunct for pathologists, particularly with the emergence of targeted therapies. The intent of this article is to share our experience, over two years, as an early adopter of targeted RNA-sequencing as an ancillary diagnostic technique for fusion gene detection in bone and soft tissue neoplasms. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app